The current study provides a comprehensive evaluation of the use of T 2 relaxation rates estimated from dual echo turbo spin echo images to objectively define nonenhancing tumor burden in patients with gliomas. Results suggest T 2 measurements are relatively stable across scanners and may be useful for delineating nonenhancing tumor from other tissues. Results also suggest the use of T 2 -defined nonenhancing tumor burden may be useful for prognostic and response assessment purposes. Experimental Design: A series of experiments were performed to establish the use of T2 maps for defining NET burden. First, variation in T2 was determined using ACR water phantoms in 16 scanners evaluated over 3 years. Next, sensitivity and specificity of T2 maps for delineating NET from other tissues was examined. Then, T2-defined NET was used to predict survival in separate subsets of glioblastoma patients treated with radiation therapy, concurrent radiation and chemotherapy, or bevacizumab at recurrence.
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STATEMENT OF TRANSLATIONAL RELEVANCE
The current study provides a comprehensive evaluation of the use of T 2 relaxation rates estimated from dual echo turbo spin echo images to objectively define nonenhancing tumor burden in patients with gliomas. Results suggest T 2 measurements are relatively stable across scanners and may be useful for delineating nonenhancing tumor from other tissues. Results also suggest the use of T 2 -defined nonenhancing tumor burden may be useful for prognostic and response assessment purposes. 
INTRODUCTION
The use of contrast enhancing tumor burden has been the standard for brain tumor response assessment for more than 60 years; however, approximately 30-40% of patients are estimated to experience nonenhancing tumor progression prior to changes in contrast enhancement (1, 2) .
Although contrast enhancing tumor is thought to represent the most aggressive portion of the tumor (3, 4) and a large percentage of high grade gliomas have a significant enhancing component (5) , malignant gliomas are known to contain proportions of both neovascularized and infiltrative tumor (6, 7) . Since a substantial proportion of treated tumors can have nonenhancing tumor progression (1, 6) , and progression of nonenhancing tumor can lead to neurologic decline, there is an emergent need for consideraton of nonenhancing tumor burden in an updated response criteria in neuro-oncology, which was further outlined in the Jumpstarting Brain Tumor Drug Development Coalition and Food and Drug Administration (FDA) Workshop in January 2014 (8, 9) . Damadian (10) first documented distinct differences in proton relaxation rates between normal and cancerous tissues as early as 1971, which was also confirmed by various groups in the subsequent years (11) (12) (13) (14) (15) . Clinical diagnosis and monitoring of brain tumors with MRI, however, remains reliant on the use of T 1 or T 2 "weighted" images, which express qualitative changes in the MR signal. T 2 relaxometry can theoretically be performed using a simple modification to the standard T 2 -weighted MRI sequence that results in obtaining multiple images at various echo times, which is essentially "free" information (i.e. no substantial added scan time). This information can in theory be used to create quantitative maps of T 2 , which is specific for various tissue types including cancer but relatively independent of MR acquisition parameters such as echo time (TE). For example, an early study by Hoehn-Berlage et al. (16) weighted images being associated with nonenhancing tumor (17) . This difference in T 2 relaxation rates between edema, tumor, and normal tissues has been characterized in both rodent models (18) and in human tumors (19) (20) (21) . Additionally, studies have shown that T 2 relaxation tends to be monoexponential (16) , suggesting evaluation of nonenhancing tumor may be possible with a single T 2 parameter. We hypothesize that "effective" T 2 relaxometry performed using the turbo spin echo may be useful for objectively defining nonenhancing tumor tissue using a specific range of T 2 values.
Accurate measurements of T 2 relaxation times typically involve using relatively time inefficient multiecho Carr-Purcell-Meiboom-Gill (CPMG) sequences. Dual echo turbo spin echo (TSE) sequences are an attractive clinical alternative to CPMG sequences (22, 23) , allowing for "effective" T 2 estimation (T 2 eff ) in clinically feasible scan times and clinically useful spatial coverage for a variety of anatomical locations (24) (25) (26) (27) (28) . In the current study we examined the stability of T 2 eff estimates in a standard water phantom across a variety of scanners, used dual echo TSE data from 50 patients with a range of glioma grades scanned on a variety of scanners and field strengths to define T 2 eff characteristics for various tissues, then applied this information to a cohort of newly diagnosed glioblastoma patients treated with radiation therapy, a cohort of newly diagnosed glioblastoma patients treated with concurrent radiation therapy and temozolomide, and a set of recurrent glioblastoma patients treated with bevacizumab to determine whether the volume of T 2 eff -defined nonenhancing tumor can be used to predict progression-free (PFS) and overall survival (OS).
Research. 
METHODS
Summary of Experiments
A series of experiments were performed in the current study to establish the use of T 2 eff in defining nonenhancing tumor burden for use in quantification of tumor burden and response assessment. First, the normal variation expected in T 2 eff estimates was determined on the American College of Radiology (ACR) standard water phantom using dual echo TSE images collected for 16 different scanners and field strengths. Next, the sensitivity and specificity of T 2 eff in delineating nonenhancing tumor from edema, necrotic tissue, and normal-appearing brain tissue was estimated in a training set of 50 glioma patients in order to define cutoffs for defining nonenhancing tumor. Using thresholds defined by these training data, we examined an independent set of 25 newly diagnosed glioblastoma patients who were treated with radiation therapy, but no concurrent temozolomide and never were exposed to bevacizumab, to determine whether nonenhancing tumor burden evaluated at this post-radiation therapy time point could predict PFS and OS. Then, another independent set of 35 glioblastoma patients treated with concurrent radiation therapy and temozolomide, but were never exposed to bevacizumab, were evaluated at the postradiation therapy time point to determine whether nonenhancing tumor burden prior to adjuvant therapy could predict PFS and OS. Lastly, we examined a set of 24 recurrent glioblastoma patients treated with bevacizumab to determine whether the change in nonenhancing tumor burden could be used to predict PFS and OS.
Phantom Studies
Research. was determined for the entire phantom at slice 6 using the standard ACR slice prescription, corresponding to a slice containing relatively homogeneous signal intensity and no internal geometric structures.
Patients
A total of 134 patients with gliomas who were evaluated using dual echo TSE between 2000-2008 were retrospectively evaluated in the current study. All patients gave informed written consent to be included in our institutional review board approved neuro-oncology database prior to this study. These 134 patients were broken into 4 groups for training and testing purposes: 1) 50
Research. patients with various glioma grades used for training; 2) 25 newly diagnosed glioblastoma patients treated with radiation therapy and no concurrent chemotherapy, none of which ever were exposed to bevacizumab; 3) 35 newly diagnosed glioblastoma patients treated according to the current standard of care including radiation therapy with concurrent temozolomide (TMZ), followed by adjuvant TMZ; and 4) 24 recurrent glioblastoma patients treated with bevacizumab.
Because this was a retrospective study, sample sizes were based solely on availability of data in patients that met the inclusion criteria outlined below. gray-white matter junction, no significant mass effect, and presence of "finger-like" projections of high intensity T2 signal within deep white matter, as defined previously by Pope et al. (17) .
The average T2 eff for these regions were retained and used to define field-strength-specific thresholds to accurately delineate nonenhancing tumor from both edema and NAWM using Receiver-Operator Characteristic (ROC) analysis. 
Recurrent Glioblastoma Treated with
Bevacizumab. An independent sample of 24 patients with recurrent glioblastoma (average age = 56, range = 27-91 years old; average KPS = 82, range 70-100; 12/24 were male (50%)) who failed IMRT and TMZ who also underwent evaluation at recurrence (baseline) and 2-4 weeks after the first administration of bevacizumab (10 mg/kg intravenously every 14 days) using dual echo TSE between 2000-2008 were retrospectively evaluated ( Figure 1C ). All patients were treated with bevacizumab every 14 days until disease progression or death.
Magnetic Resonance Imaging
Research. and field of view, 24-25.6 cm) and a fluid-attenuated inversion-recovery sequence. In addition, axial T1-weighted images enhanced with gadopentetate dimeglumine (Magnevist; Berlex), 0.1 mmol/kg, and acquired shortly after contrast material injection, were matched to nonenhanced T1-weighted images obtained with similar sequence parameters. Dual echo TSE images for the training dataset included both proton density/T2-weighted imaging pairs (e.g. TE 1 =5-10ms, TE 2 =80-120ms) or two sets of T2-weighted images (e.g. TE 1 =80-120ms, TE 2 =160-200ms). All therapeutic evaluations in the current study were collected on a 1.5T MR scanner (Avanto or Sonata, Siemens Healthcare, Erlangen, Germany; Excite HDx or LX, GE Medical Systems, Waukesha, WI) and all dual echo TSE images had full brain coverage with TE 1 = 9-15ms, TE 2 =118-135ms, TR = 4000ms, matrix size = 256x256, FOV = 240mm, and slice thickness = 3mm with no interslice gap.
Definition of Disease Progression
Progression was defined prospectively by the treating neuro-oncologists using a method consistent with the current RANO criteria (29) . In particular, progression was defined if subsequent scans showed an increase in imaging-evaluable tumor (≥ 25% increase in the sum of enhancing Landmark overall survival (OS) was defined as the number of days between the post-treatment MRI scan to death.
Automated Segmentation and Quantification of Nonenhancing Tumor Burden
Multiple studies have demonstrated that the T 2 characteristics for nonenhancing tumor fall between T 2 measurements of NAWM and edema (i.e. T 2 eff NAWM < T 2 eff tumor < T 2 eff edema ) (16) (17) (18) (19) (20) (21) .
The particular thresholds used for tumor segmentation were determined empirically from the 50 glioma patients as per the experiment described above. After defining these thresholds, a 3 step automated procedure was performed to segment regions of nonenhancing tumor from surrounding tissues (Supplemental Figure A) : 1) First, the skull was stripped and all tissue with T 2 eff greater than the threshold to delineate tumor and NAWM were isolated, effectively removing NAWM and retain tumor, edema, and necrosis. 2) Next, one image voxel surrounding these regions was eroded in order to remove tissues on the border of edema and NAWM, for example, 
Newly Diagnosed Glioblastoma Treated with Radiotherapy. For newly diagnosed glioblastoma patients treated with radiation alone followed by adjuvant chemotherapy, ROC analysis was used to determine whether the volume of NET burden (selected from ROC analysis of training data) could stratify patients who progressed 6 months as well as those who expired within 9 months following completion of radiation therapy. Log-rank univariate analysis applied to Kaplan-Meier data was used to determine whether patients with a large NET burden (from ROC analysis) had significantly shorter PFS and OS. A Cox multivariate proportional hazards model was then used to determine whether NET volume quantified using T 2 eff was an independent predictor of PFS and OS after including covariates including patient age and KPS.
Newly Diagnosed Glioblastoma Treated with Concurrent Radiotherapy and Temozolomide
Followed by Adjuvant Temozolomide. For newly diagnosed glioblastoma patients treated with concurrent radiation and temozolomide followed by adjuvant temozolomide, ROC analysis was used to determine whether the volume of NET burden (selected from ROC analysis of training data) could stratify patients who progressed 6 months as well as those who expired within 9 months following completion of radiation therapy. Log-rank univariate analysis applied to Kaplan-Meier data was used to determine whether patients with a large NET burden (from ROC analysis) had significantly shorter PFS and OS. A Cox multivariate proportional hazards model was then used to confirm whether NET burden quantified using T 2 eff was an independent predictor of PFS and OS after including covariates including patient age and KPS.
Recurrent Glioblastoma Treated with Bevacizumab. For recurrent glioblastoma patients treated with bevacizumab, ROC analysis was used to determine whether the volume of NET burden (selected from ROC analysis of training data) could stratify patients who progressed 6
17 months as well as those who expired within 9 months following start of bevacizumab. Log-rank univariate analysis applied to Kaplan-Meier data was used to determine whether small changes in NET burden (from ROC analysis) had significantly shorter PFS and OS. A Cox multivariate proportional hazards model was then used to confirm that change in NET burden before and after bevacizumab was an independent predictor of PFS and OS after including covariates including patient age and KPS. 
RESULTS
Evaluations of the ACR phantoms using the dual echo TSE sequence showed reasonable stability over time, averaging a coefficient of variance of approximately 3.4% for 3T scanners and 4.5% for 1.5T scanners when evaluated over the last 3 years. The coefficient of variance of T 2 eff measurements across the 3T scanners was 3.1% and across all 1.5T scanners was 4.5%, suggesting long-term stability was similar to the stability across scanners at a single time point. T 2 eff measurements on 3T MR scanners were significantly lower than 1.5T scanners (Figure 2 threshold of 125ms could be used to stratify NET from NAWM with a sensitivity of sensitivity of 96% and specificity of 97% at 1.5T, and 94% sensitivity and 97% specificity at 3T. Thus, we propose using a range of T 2 eff values between 125ms < T 2 eff < 250ms, on both 1.5T and 3T MR scanners, to objectively define NET for the purpose of tumor burden quantification. Figure 4C shows a patient with a recurrent glioblastoma containing a large, well-circumscribed NET appearing as slightly T 2 hyperintense on T2-weighted images at 3T. T 2 eff maps clearly show that this NET falls largely within the defined range of 125ms < T 2 eff < 250ms. Conversely, Figure 4D also shows a patient with recurrent glioblastoma scanned at 3T with a large extent of edematous tissue, as demonstrated by the "finger like" extensions of very bright T 2 hyperintensity on T 2 -weighted images. Consistent with these qualitative observations, most of this lesion had elevated Next, we aimed to test whether the volume of NET burden following radiation therapy combined with temozolomide followed by adjuvant temozolomide was a prognostic predictor in patients with newly diagnosed glioblastoma ( Figure 5D-F Lastly, we tested whether early NET response measured as the change in NET volume before and after bevacizumab therapy could be used to predict survival in patients with recurrent glioblastoma ( Figure 5G-I) . The average volume of NET burden for the cohort prior to and after bevacizumab therapy was estimated at 30.3cc ± 3.7cc (S.E.M.) and 15.8cc ± 3.5cc (S.E.M.), respectively. The average change in NET volume was -14.5cc ± 2.7cc (S.E.M.). Results demonstrated that changes in NET volume before and after bevacizumab therapy could be used to identify patients who progressed within 6 months of completion of the first dose of bevacizumab ( Figure 5G ; ROC AUC = 0.7786 ± 0.0967, P = 0.022), as well as patients who expired within 9 months of completion of the first dose of bevacizumab ( Figure 5G ; ROC AUC = 0.8681 ± 0.07399, P = 0.002). A decrease in NET volume greater than 50% was found to have a sensitivity of 70% and specificity of 71% for identifying patients that will progress within 6 months of starting bevacizumab therapy, along with a sensitivity of 83% and specificity of 67% for identifying patients that will expire within 9 months of starting bevacizumab therapy. Patients showing a "response", or more than 50% decrease in NET volume after bevacizumab therapy, had a significantly longer PFS ( Figure 5H 
DISCUSSION
Results from the current study support the hypothesis that T 2 maps quickly obtained using dual echo TSE images can be used to objectively define and quantify NET burden. Results support the concept that quantification of NET is clinically meaningful and prognostic, as demonstrated both by the prognostic significance of NET tumor burden following radiation therapy with or without temozolomide as well as the change in NET volume as a simple response measure during bevacizumab therapy in recurrent glioblastoma. This is a particularly timely question as this concept has come into serious debate recently (30) . In particular, studies have suggested Results demonstrate that T 2 eff measurements using dual echo TSE are relatively stable, varying approximately 3-5% over time and across scanners of similar field strength when evaluated in phantoms. This is consistent with previous reports showing variation in normal tissues of between 5-15% (23, 33, 34) , on par with errors due to the specific pulse sequence and vendor specific errors (35) . T 2 estimation using dual echo TSE techniques, however, has been shown to slightly overestimate T 2 by as much as 10% (26, (36) (37) (38) . This bias in T 2 estimation arises from multiple sources, including the use of only a few echoes for estimation, spurious signals from stimulated echoes, radiofrequency pulse imperfections, and different phase encoding profile orders (26, 39, 40) . Despite this inaccuracy, T 2 mapping using dual echo TSE acquisition has proven very useful for identification of various pathologies, including Alzheimer's and other neurodegenerative diseases (23, 37, 41, 42) . Techniques to overcome this slight bias have been developed (39), although they remain relatively cumbersome to implement and are not often used in clinical practice. Importantly, the Alzheimer's disease neuroimaging initiative (ADNI) chose to implemented dual echo T 2 -weighted TSE for estimation of pathology-specific changes in quantitative T 2 ; thus, a standardized dual echo TSE sequence is openly available from all major MRI vendors, which further supports the view of using dual echo T2-weighted TSE to quantify "ef- Additional considerations and study limitations should also be addressed. For example, white matter changes after radiation therapy may have confounded our interpretation of various tissue types; however, we strategically included recurrent glioma patients in our training cohort in order to provide a more robust range of T2 values that might include treatment-related changes. Lastly, the current study lacks separate, independent validation of the primary findings. Future studies aimed at independent validation in a randomized clinical trial, along with comparison to other imaging biomarkers, is warranted in order to establish effective T 2 maps as a surrogate for quantifying NET burden in patients with gliomas. 
